Business Context and Reporting Period
This Form 6-K filing by Ambev S.A. covers the month of September 2015, with the report signed on October 10, 2015. The document serves as a disclosure of securities transactions involving the company's Board of Directors, Management, and Fiscal Council, in compliance with Article 11 of CVM Instruction # 358/2002.
Key Financial Metrics
The filing text does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting share ownership balances and transaction volumes for related persons.
| Group | Initial Common Shares | Final Common Shares | Ownership % |
|---|---|---|---|
| Management | 7,763,714 | 7,814,595 | 0.0497% |
| Board of Directors | 11,302,867,595 | 11,303,010,045 | 71.9130% |
| Fiscal Council | 7,225 | 7,225 | 0.0000% |
Material Changes
Material changes in shareholdings occurred within the Management and Board of Directors groups during September 2015:
- Management: Net increase of 50,881 shares. This resulted from exercising options (25 shares) and buying 67,200 shares, offset by selling 16,319 shares through various intermediaries and direct transactions.
- Board of Directors: Net increase of 142,450 shares. Significant activity included a capital increase transaction involving 20,400,000 shares and option exercises, partially offset by sales.
- Fiscal Council: No change in shareholding balance.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is a regulatory compliance report regarding insider trading and does not discuss operational strategy or future performance.
Investor Verification Checklist
- Verify the total number of shares outstanding to confirm the accuracy of the reported ownership percentages (e.g., Board holding ~71.91%).
- Review the specific terms of the "Capital increase" transaction involving 20.4 million shares to understand the dilution impact or funding purpose.
- Confirm the pricing of the option exercises (R$ 4.14 and R$ 7.47) against the market price at the time of exercise to assess potential gains.
- Check subsequent filings for the full 2015 fiscal year results, as this document contains no revenue or earnings data.